Immutep Ltd (IMMP) News

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to...

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results...

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the...

Immutep Quarterly Activities Report Q1 FY25

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell...

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

Media Release First safety data anticipated before year end with assessment of PK/PD relationships to follow...

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

Media Release SYDNEY, AUSTRALIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]